Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Javier Pérez-Villavicencio has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Ozone as a Catalyst for Alzheimer’s Disease and Sleep Disorders: Implications for Neurodegeneration Induced by Air Pollution

    by Alejandro López-Landa, Emiliano González-Sánchez, Javier Pérez-Villavicencio, Norma Serrano García, Carlos García-Hernández, Ángel Lee, Moisés Rubio-Osornio, Carmen Rubio

    Tropospheric ozone, a highly reactive air pollutant, has emerged as a potential environmental risk factor for Alzheimer’s disease (AD) and its associated sleep disturbances, yet a comprehensive synthesis of the underlying mechanisms has remained limited. This narrative review summarizes experimental and epidemiological evidence on ozone exposure, neurodegeneration and disrupted sleep, organized around one working hypothesis: ozone generates a systemic oxidative–inflammatory signal that reaches the central nervous system, with sleep/circadian disruption and AD-related pathology as downstream outcomes that may reinforce each other. In experimental models, ozone is associated with oxidative stress, mitochondrial dysfunction, blood–brain barrier disruption, glial activation and neuroinflammation, overlapping with β-amyloid accumulation and tau hyperphosphorylation, and with reduced REM sleep and altered neurotransmitters; clock-gene changes have been shown mainly in peripheral tissue. Circadian disruption is a candidate effector, and current data cannot distinguish mediation from co-occurrence. Epidemiological evidence for ozone-specific associations with cognitive decline remains inconsistent at the population level compared with other pollutants such as PM2.5 or NO2, although some cohorts report pollutant-specific effects and modulation by the apolipoprotein E ε4 (APOE4) genotype. Most experimental studies use concentrations well above regulatory ambient standards. Overall, ambient ozone is a biologically plausible, but not yet epidemiologically confirmed, candidate risk factor for AD and sleep disorders. Future work should prioritize exposure-graded longitudinal studies and clarification of the dose–response relationship, including the effects of controlled medical ozone.

  • Open Access

    Interaction Between Glial Cells and Cerebellar Circuits in Epilepsy

    by Javier Pérez-Villavicencio, Ricardo Pérez-Rubio Flores, Héctor Romo-Parra, Carmen Rubio

    The cerebellum, long studied as the principal center for motor coordination, is now recognized as a participant in epileptogenic network dynamics through the pathway running from the cerebellar cortex to the deep cerebellar nuclei and on to thalamic and cortical targets. Purkinje cells are the sole inhibitory output of the cerebellar cortex, and Bergmann glia, a radial astrocyte population apposed to Purkinje cell dendrites and parallel-fiber synapses, sustain the perisynaptic environment on which Purkinje cell firing depends through glutamate clearance by GLAST/EAAT1, potassium buffering by Kir4.1, and calcium-dependent signaling. In cortex and hippocampus, loss of the equivalent functions in protoplasmic astrocytes lowers seizure threshold and produces spontaneous seizures, but no comparable experiment has been performed in Bergmann glia. Molecular genetics has identified numerous epilepsy-associated genes, of which only SLC1A3, KCNJ10 and AQP4 have cell-type-resolved expression in Bergmann glia; the remainder act on cerebellar circuits through neurons. In human epilepsy, cerebellar atrophy with Purkinje cell loss and Bergmann gliosis tracks cumulative seizure burden and antiseizure medication exposure rather than a primary cerebellar lesion and is therefore best read as reactive. Reactive astrogliosis is nonetheless accompanied by reduced glutamate transport and potassium buffering in sclerotic hippocampus, and whether cerebellar reactive gliosis carries the same homeostatic cost has not been measured. This review sets out the circuit-level, genetic and neuropathological evidence bearing on that question and specifies the experiments that would answer it.

  • Open Access

    Parkinson’s Disease, Microglia, and Extracellular Matrix Remodeling

    by Norma Serrano-García, Alexis Ponce-Juárez, Maximiliano Ganado, Javier Pérez-Villavicencio, Moisés Rubio-Osornio

    Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by the selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) and the intracellular accumulation of alpha-synuclein (α-syn) aggregates. Historically, research has focused on neuronal mechanisms; however, growing evidence indicates that the progression of neurodegeneration is influenced by changes in the brain microenvironment, particularly through the dynamic interplay between microglia and the extracellular matrix (ECM). ECM in the central nervous system is an organized network of structural proteins, glycoproteins, and proteoglycans that encases neurons and glial cells, regulating processes such as synaptic stability, neural plasticity, and intercellular signaling. In PD, the aggregation of α-syn and neuronal damage induce sustained microglial activation, which can alter ECM structure. Activated microglia release proteases, including matrix metalloproteinases and cathepsins, which can degrade critical ECM components such as collagens, laminins, and proteoglycans. This remodeling can modify synaptic architecture, regulate cellular signaling, and disrupt neuron-glia interactions, fostering an environment conducive to dopaminergic degeneration. Furthermore, ECM remodeling and microglial activation exhibit regional variability within the brain. Regions notably prone to degeneration, such as the SNpc and striatum, display significant alterations in matrix organization and inflammatory activity, while other dopaminergic regions, including the ventral tegmental area, show increased resilience. We suggest that microglia-mediated ECM remodeling serves as a mechanistic link between neuroinflammation and neuronal susceptibility in PD. This review consolidates the existing knowledge on microglial modulation of ECM dynamics during neurodegeneration, explores regional differences in these processes, and evaluates their significance as possible treatment targets.

  • Open Access

    Huntington’s Disease as a Neuroglial Systems Disorder: Mechanisms, Network Propagation, and Therapeutic Opportunities

    by Javier Pérez-Villavicencio, Omar Villa-Robledo, Ximena Megchun-Vázquez, Fernando Uriarte-Jiménez, Moisés Rubio-Osornio, Norma Serrano-García

    Huntington’s disease (HD) has traditionally been conceptualized as a neuron-centric disorder primarily attributed to cell-autonomous toxicity of mutant huntingtin (mHTT) in striatal medium spiny neurons. However, this framework inadequately explains the prolonged presymptomatic phase, selective network vulnerability, early non-motor manifestations, and limited success of neuron-targeted therapeutic interventions. Accumulating evidence from molecular biology, transcriptomics, neuroimaging, and preclinical therapeutics supports a reframing of HD as a disorder of neuroglial systems dysfunction. We synthesize data demonstrating that astrocytes, microglia, and oligodendrocyte lineage cells are not passive bystanders but play direct and interactive roles in HD pathogenesis through defined molecular mechanisms. Expression of mHTT in glial populations impairs synaptic homeostasis, metabolic coupling, immune resolution, and myelin integrity, generating self-amplifying pathological feedback loops that destabilize neural circuits long before overt neuronal death. Critically, we evaluate glial replacement therapy as a potential disease-modifying strategy. Preclinical studies demonstrate that transplantation of healthy human glial progenitor cells substantially ameliorates motor, cognitive, and neuropathological deficits in multiple HD models through oligodendroglial remyelination and lactate-mediated metabolic support, despite persistent neuronal mHTT expression. Effective HD therapy will likely require strategies that jointly target the genetic cause and the dysfunctional neuroglial microenvironment. By integrating systems neuroscience with glial biology and translational strategy, this review defines a neuroglial framework for HD that opens a plausible path toward meaningful disease modification and positions HD as a model disorder for glial-centric interventions in neurodegeneration.

  • Open Access

    Antiseizure Medications Impact Mitochondrial Ion Channels via Novel Bioenergetic and Neural Mechanisms

    by Carmen Rubio, Norma Serrano-Garcia, Ricardo Pérez-Rubio, Javier Pérez-Villavicencio, Héctor Romo-Parra, Ángel Lee, Moisés Rubio-Osornio

    Antiseizure medications (ASMs) have traditionally been characterized by their modulation of neuronal ion channels and synaptic processes; however, accumulating evidence indicates that numerous ASMs also directly modulate mitochondrial function. Specifically, several ASMs interact with ion channels located in both the inner and outer mitochondrial membranes, including the voltage-dependent anion channel (VDAC), the mitochondrial calcium uniporter (MCU), the mitochondrial Na+/Ca2+ exchanger (NCLX), the mitochondrial permeability transition pore (mPTP), and mitochondrial ATP-sensitive potassium channels (mitoKATP). Modulation of these channels regulates critical processes in epilepsy, including Ca2+ homeostasis, ATP synthesis, redox equilibrium, and susceptibility to neuronal apoptosis. Phenytoin and carbamazepine reduce voltage-dependent anion channel isoform 1 (VDAC1)-associated mitochondrial permeability by modulating the Bcl-2-associated X protein (Bax)/B-cell lymphoma 2 protein (Bcl-2) ratio; ethosuximide limits mitochondrial Ca2+ overload through modulation of the MCU complex; valproic acid stabilizes NCLX function and prevents mPTP opening via antioxidant mechanisms; levetiracetam contributes to preserving intracellular Ca2+ handling; and mitoKATP activators, including diazoxide and retigabine, promote mitochondrial membrane potential stability and reduce seizure-induced reactive oxygen species (ROS) generation. The mitochondrial effects vary according to epilepsy subtype, contributing to the attenuation of hippocampal apoptosis in temporal lobe epilepsy and thalamocortical network modulation in generalized epilepsies. In this narrative review we examine the experimental and molecular evidence demonstrating how ASMs modulate mitochondrial ion channels and how these interactions contribute to their anticonvulsant mechanisms, thereby broadening the understanding of mitochondria as key functional components in antiseizure pharmacology.

  • Open Access

    Dysregulation of the Extracellular Matrix in the Synaptic Pathology of Parkinson’s Disease: Molecular Mechanisms and Novel Therapeutic Approaches

    by Carmen Rubio, Ricardo Pérez-Rubio, Javier Pérez-Villavicencio, Norma Serrano-García, Ángel Lee, Leticia Granados-Rojas, Martha Tena-Suck, Moisés Rubio-Osornio

    Parkinson’s disease (PD) is defined by the progressive degeneration of dopaminergic neurons within the substantia nigra and the pathological accumulation of α-synuclein (α-syn) aggregates. Beyond these intracellular hallmarks, the extracellular matrix (ECM) has emerged as an active regulator of synaptic dysfunction, neuroinflammation, and disease progression. Recent multi-omics evidence, including transcriptomic and proteomic profiling of post-mortem tissue and iPSC-derived neurons, demonstrates consistent dysregulation of ECM components across both sporadic and genetic PD subtypes—typified by downregulation of basement membrane collagens (COL4A) and integrin signaling (ITGB1), alongside upregulation of matrix metalloproteinases (MMPs). These alterations destabilize perineuronal nets (PNNs), allow prion-like α-syn propagation, and promote glial activation through TLR-mediated signaling. Circulating ECM-derived neoepitopes (C1M, C4M) may complement neurofilament light chain as prognostic biomarkers of disease progression, although prospective validation remains necessary. Pharmacological strategies targeting MMP activity (e.g., doxycycline), integrin–FAK signaling (ATN-161), and MMP–TIMP balance (mesenchymal stem cells) represent emerging therapeutic avenues, though clinical evidence in PD remains limited. This review synthesizes current evidence on ECM dysregulation in PD and discusses its implications for biomarker development and disease-modifying intervention.


  • Open Access

    The Hidden Metabolic Roots of Epilepsy

    by Carmen Rubio, Sergio Carpinteyro, Norma Serrano-García, Héctor Romo-Parra, Javier Pérez-Villavicencio, Ángel Lee, Rodrigo Mercado-Pimentel, Moisés Rubio-Osornio

    The relationship between epilepsy, obesity, and metabolic syndrome (MetS) has emerged as a rapidly evolving area of neurobiology inquiry. Emerging evidence suggests that epilepsy extends beyond neuronal hyperexcitability, reframing it as a systemic condition characterized by significant metabolic dysregulation. Converging supports a bidirectional relationship while seizures, antiseizure medications (ASM), and neuroinflammation induce exacerbate potentiate epileptogenesis through shared molecular pathways. At the cellular level, chronic epileptic activity induces oxidative stress, mitochondrial dysfunction, and the activation of microglia and astrocytes. This, in turn, leads to the release of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. These mediators traverse the blood-brain barrier (BBB), subsequently modifying insulin signaling, and disrupting glucose homeostasis, which collectively fosters a pro-inflammatory and insulin-resistant environment. Furthermore, antiseizure medications such as valproate can exacerbate these effects by directly impairing insulin receptor signaling and altering adipokine production, ultimately contributing to weight gain and systemic metabolic dysregulation. Obesity and MetS induce neuroinflammatory and excitotoxic states that promote seizure onset via leptin resistance, reduced adiponectin levels, and compromised AMP-activated protein kinase (AMPK) signaling. Emerging evidence emphasizes the gut-brain axis as a crucial regulator in this reciprocal interaction. Dysbiosis, altered microbial metabolites (e.g., short-chain fatty acids), and heightened intestinal permeability facilitate systemic inflammation and BBB disruption, enhancing neuronal excitability. Insulin resistance in the brain disrupts synaptic transmission, impairs mitochondrial biogenesis, and compromises redox equilibrium, perpetuating a pathological cycle linking metabolic stress to epileptic activity. This review synthesizes the cellular, molecular, and systemic pathways connecting epilepsy, obesity, and MetS, and proposes that epilepsy be reconceptualized as a neuro-metabolic disorder. Insights into these convergent pathways provide a rationale for novel therapeutic strategies that simultaneously target seizure control and metabolic regulation, encompassing microbiota modulation, antioxidant therapy, and insulin-sensitizing interventions with the overarching aim of restoring neuro-metabolic homeostasis.


  • Open Access

    Opioid Receptors in Psychedelia: Indirect Serotonergic Modulation of Direct KOR Activation by Salvinorin A

    by Maximiliano Ganado, Carmen Rubio, Javier Pérez-Villavicencio, Norma Serrano, Héctor Romo-Parra, Ángel Lee, Moisés Rubio-Osornio

    The neuropharmacology of psychedelics has traditionally focused on serotonergic mechanisms, particularly 5-HT2A receptor activation. However, this paradigm incompletely explains the diversity of neurobiological and therapeutic effects observed across psychedelic compounds. Non-classical psychedelics such as salvinorin A, the primary active constituent of Salvia divinorum, challenge this framework through direct kappa opioid receptor (KOR) agonism, representing a serotonin-independent pathway to altered consciousness. This review systematically examines the role of the endogenous opioid system in mediating psychedelic effects, with emphasis on salvinorin A’s unique KOR-dependent mechanisms. We synthesized preclinical and clinical evidence from in vitro studies, genetically modified animal models, optogenetic circuit dissection, and human neuroimaging trials. Salvinorin A’s selective KOR activation is characterized by pronounced β-arrestin-biased signaling, distinguishing it from endogenous dynorphins and classical KOR agonists. This produces rapid receptor desensitization, transient functional plasticity, and profound dissociative effects mediated through thalamocortical disruption, mesolimbic dopaminergic suppression, and fragmentation of large-scale brain networks. Classical serotonergic psychedelics indirectly engage opioid systems through downstream 5-HT2A signaling, contributing to analgesic and mood-regulatory effects via secondary MOR/DOR modulation. Despite being a potent opioid agonist, salvinorin A exhibits low abuse potential due to aversive phenomenology, dopaminergic suppression, and absence of positive reinforcement in animal models. Incorporating opioid receptor pharmacology into psychedelic neuroscience expands mechanistic understanding beyond serotonin-centric models, revealing multiple neurochemical pathways capable of inducing therapeutically relevant altered states. This framework enables rational development of biased KOR ligands and establishes salvinorin A as a paradigmatic model for non-serotonergic psychedelia with applications in treatment-resistant depression, addiction, and chronic pain.


  • Open Access

    The Extracellular Matrix, the Silent ‘Architect’ of Glioma

    by Carmen Rubio, Javier Pérez-Villavicencio, Nadia F. Esteban-Román, Ángel Lee, Gervith Reyes-Soto, Moisés Rubio-Osornio

    The brain’s extracellular matrix (ECM) serves as a dynamic and instructive regulator of glioma progression. The ECM provides structural support while integrating pharmacological and mechanical signals that influence glioma initiation, progression, and treatment resistance. Deviant ECM remodeling fosters tumor heterogeneity, invasion, and immune evasion by altering stiffness, composition, and cellular matrix signaling. We proposed that ECM remodeling in gliomas not only facilitates tumor growth and heterogeneity but also establishes advantageous biophysical and metabolic conditions that foster treatment resistance and recurrence. Our objective is to analyze current findings regarding the structural, biochemical, and mechanical roles of the brain ECM in glioma growth, emphasizing its contribution to tumor heterogeneity, mechanotransduction, immunological modulation, and its potential as a therapeutic target. Method: A comprehensive literature review was conducted using scientific databases including PubMed, Web of Science, and Scopus. Peer-reviewed literature published between 2000 and 2025 was selected for its relevance to ECM composition, stiffness, remodeling enzymes, extracellular vesicles, and mechanobiological processes in gliomas. Results: Recent investigations demonstrate that glioma cells actively alter the ECM by secreting collagens, laminins, and metalloproteinases, establishing a feedback loop that facilitates invasion and resistance. Discussion: Mechanical variables, such as ECM stiffness and solid stress, influence glioma growth, metabolism, and immune exclusion. Moreover, extracellular vesicles facilitate significant extracellular matrix remodeling and improve communication between tumors and stromal cells. The disruption of ependymal and subventricular extracellular matrix niches enhances invasion and cerebrospinal fluid-mediated signaling. The remodeling of the ECM influences glioma growth through interconnected biochemical, mechanical, and immunological mechanisms. Examining ECM stiffness, crosslinking enzymes, and vesicle-mediated signaling represents a potential therapeutic approach. Integrative methodologies that combine mechanobiology, imaging, and multiomics analysis could uncover ECM-related vulnerabilities to improve glioma treatment.